PDE9 inhibitors for treating heart failure
Patent Information
- Application Number
- JP2023525599
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-10-27
- Filing Date
- 2021-10-26
- Publication Date
- 2024-11-01
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current therapies for heart failure, cardiac fibrosis, and myocardial inflammation are inadequate, and there is a need for improved treatments that can effectively manage these conditions, particularly in cases with preserved ejection fraction (HFpEF).
The use of Compound 1, a PDE9 inhibitor, administered at specific doses to treat heart failure, cardiac fibrosis, and myocardial inflammation by reducing biomarkers such as ANP and BNP, and inhibiting fibronectin and collagen accumulation.
Compound 1 effectively reduces biomarkers and pathological processes associated with heart failure and cardiac fibrosis, improving cardiac function and reducing inflammation, with potential for combination therapies and varied administration routes.
Abstract
Description
[Technical Field]
[0001] cross reference This application claims the interests of U.S. Patent Application No. 63 / 106,301, filed on 27 October 2020, which is incorporated herein by reference in its entirety. [Background technology]
[0002] Heart failure (HF), or cardiac failure, is a condition in which the heart is unable to adequately pump blood to maintain the body's blood flow. Common causes of heart failure include, among others, coronary artery disease, hypertension, atrial fibrillation, valvular heart disease, excessive alcohol consumption, infections, and cardiomyopathy. Heart failure is a common, costly, and potentially fatal condition. In 2015, approximately 40 million people worldwide were diagnosed with heart failure. Two percent of all adults are affected by heart failure, and this increases to 6-10% for those 65 years of age and older. The risk of death within one year of diagnosis is approximately 35%. There is an urgent need to develop improved therapies for heart failure and other related heart diseases. [Overview of the project]
[0003] This disclosure provides a method for using a pharmaceutical composition comprising Compound 1 and / or Compound 1 or a pharmaceutically acceptable salt, solvate, or polymorph thereof to treat cardiovascular diseases, including heart failure, cardiac fibrosis, and myocarditis.
[0004] One aspect of the present disclosure is a method for treating heart failure in a patient requiring treatment, comprising administering a PDE9 inhibitor, for example, 6-[4-methyl-1-(pyrimidine-2-ylmethyl)pyrrolidine-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazine-8-one (compound 1), or a pharmaceutically acceptable salt, solvate, or polymorph thereof, to a subject requiring treatment for heart failure, wherein the compound is administered in a dose greater than or less than 10 mg / kg per body weight of the patient.
[0005] In some embodiments, heart failure is acute heart failure, chronic heart failure, or congestive heart failure. In some embodiments, heart failure is diabetes-induced heart failure, autoimmune heart failure, or inflammatory heart failure. In some embodiments, heart failure is heart failure with preserved ejection fraction or heart failure with reduced ejection fraction.
[0006] One aspect of the present disclosure is a method for treating cardiac fibrosis in a patient requiring treatment, comprising administering a PDE9 inhibitor, such as 6-[4-methyl-1-(pyrimidine-2-ylmethyl)pyrrolidine-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazine-8-one (compound 1), or a pharmaceutically acceptable salt, solvate, or polymorph thereof, to a subject requiring treatment for cardiac fibrosis.
[0007] In some embodiments, the treatment of cardiac fibrosis further includes reducing the accumulation of fibronectin and / or type I and type II collagen.
[0008] One aspect of the present disclosure is a method for treating myocarditis in a patient requiring treatment, comprising administering a PDE9 inhibitor, such as 6-[4-methyl-1-(pyrimidine-2-ylmethyl)pyrrolidine-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazine-8-one (compound 1), or a pharmaceutically acceptable salt, solvate, or polymorph thereof, to a subject requiring treatment for myocarditis.
[0009] One aspect of the present disclosure is a method for reducing ANP and / or BNP in a patient requiring such reduction, comprising administering a PDE9 inhibitor, such as 6-[4-methyl-1-(pyrimidine-2-ylmethyl)pyrrolidine-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazine-8-one (compound 1), or a pharmaceutically acceptable salt, solvate, or polymorph thereof, to a subject requiring such reduction.
[0010] In some embodiments, ANP decreases by approximately 5%, 10%, 20%, 30%, 40%, or 50%, or more, compared to pre-treatment levels. In some embodiments, BNP decreases by approximately 5%, 10%, 20%, 30%, 40%, or 50%, or more, compared to pre-treatment levels.
[0011] In some embodiments of the method, the PDE9 inhibitor is administered to the patient at a dose of approximately 1 mg / kg to approximately 10 mg / kg per body weight. In some embodiments, the PDE9 inhibitor is administered to the patient at a dose of approximately 2 mg / kg, approximately 3 mg / kg, approximately 4 mg / kg, approximately 5 mg / kg, approximately 6 mg / kg, approximately 7 mg / kg, approximately 8 mg / kg, or approximately 9 mg / kg per body weight. In some embodiments of the method, the PDE9 inhibitor is administered to the patient at a dose of approximately 10 mg / kg to approximately 500 mg / kg per body weight. In some embodiments, the PDE9 inhibitor is administered to the patient at a dose of approximately 50 mg / kg, approximately 100 mg / kg, approximately 150 mg / kg, approximately 200 mg / kg, or approximately 250 mg / kg per body weight. In some embodiments, the PDE9 inhibitor is administered to the patient at a dose of approximately 60 mg / kg or approximately 100 mg / kg per body weight. In some embodiments, the PDE9 inhibitor is administered to the patient in doses of approximately 100 mg to approximately 800 mg. In some embodiments, the PDE9 inhibitor is administered to the patient in doses of approximately 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, or 800 mg. In some embodiments, the PDE9 inhibitor is administered to the patient in QD, BID, or TID.
[0012] In some embodiments, the PDE9 inhibitor is administered together with at least one additional therapeutic agent. In some embodiments, the additional therapeutic agent is selected from angiotensin transferase inhibitors (ACEIs), β-receptor blockers, mineralocorticoid / aldosterone receptor antagonists (MRAs), diuretics, angiotensin receptor neprilysin inhibitors (ARNIs), neprilysin inhibitors (NEPIs), angiotensin II receptor blockers (ARBs), vasodilators, and hydralazine (HYD) or isosorbide dinitrate (SND), or a combination thereof. In some embodiments, additional therapeutic agents are selected from hydroxyurea (HU), captopril, enalapril, lisinopril, trandolapril, bisoprolol, carvedilol, metoprolol succinate, nebivolol, eplerenone, spirolactone, sacubitril, ivabradine, candesartan, valsartan, digoxin, deslanoside, dopamine, dobutamine, dopexamine, milrinone, enoximon, phosphocreatine, cyclohexylethylamine, nitroglycerin, isosorbide dinitrate, sodium nitroprusside, prazosin, ivabradine, candesartan, valsartan, furosemide, bumetanide, torasemide, bendrofluazide, hydrochlorothiazide, metrazone, indapamide, amiloride, and triamterene. In some embodiments, the PDE9 inhibitor and at least one additional therapeutic agent are administered concurrently or sequentially. In some embodiments, the PDE9 inhibitor is administered orally. In some embodiments, the PDE9 inhibitor is administered daily. In some embodiments, the PDE9 inhibitor is administered for 1 to 7 days.In some embodiments, the PDE9 inhibitor is administered for at least 7 days.
[0013] Incorporation by reference All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
Brief Description of the Drawings
[0014] [Figure 1A] Figures 1A and 1B show that Compound 1 (IMR-687) reduces heart size and cardiomyocyte hypertrophy in the angiotensin II infusion model when dosed at 60 and 100 mg / kg for 6 weeks. [Figure 1B] Figures 1A and 1B show that Compound 1 (IMR-687) reduces heart size and cardiomyocyte hypertrophy in the angiotensin II infusion model when dosed at 60 and 100 mg / kg for 6 weeks. [Figure 2A] Figures 2A and 2B show that Compound 1 (IMR-687) reduces heart size and cardiomyocyte hypertrophy in the nephrectomy-aldosterone model after dosing at 60 and 100 mg / kg for 4 weeks. [Figure 2B] Figures 2A and 2B show that Compound 1 (IMR-687) reduces heart size and cardiomyocyte hypertrophy in the nephrectomy-aldosterone model after dosing at 60 and 100 mg / kg for 4 weeks. [Figure 3A] Figures 3A and 3B show that Compound 1 (IMR-687) reduces the ANP marker and BNP marker of heart failure after dosing at 60 and 100 mg / kg in combination with angiotensin II (left side) or nephrectomy-aldosterone (right side). Figure 3A shows the ANP biomarker and Figure 3B shows the BNP biomarker. [Figure 3B]Figures 3A and 3B show that compound 1 (IMR-687), administered at 60 and 100 mg / kg in combination with angiotensin II (left) or nephrectomy-aldosterone (right), reduces ANP and BNP markers for cardiac dysfunction. Figure 3A shows the ANP biomarker, and Figure 3B shows the BNP biomarker. [Figure 4A] Figures 4A and 4B show that administration of compound 1 (IMR-687) in combination with angiotensin II (4A) or nephrectomy-aldosterone (4B) increases the expression of HFpEF, PDE5, and PDE9, and leads to decreased cGMP levels, decreased PKG activity, and excessive Ca++ channel activity. [Figure 4B] Figures 4A and 4B show that administration of compound 1 (IMR-687) in combination with angiotensin II (4A) or nephrectomy-aldosterone (4B) increases the expression of HFpEF, PDE5, and PDE9, and leads to decreased cGMP levels, decreased PKG activity, and excessive Ca++ channel activity. [Figure 5] Figure 5 shows that angiotensin II induces cardiomyopathy through the expression of TGF-β, accumulation of fibronectin, and type I and type II collagen (ScientificReports|6:37635|DOI:10.1038 / srep37635). [Figure 6A] Figures 6A and 6B show that compound 1 (IMR-687), in combination with angiotensin II, reduces cardiac fibrosis by blocking TGF-β1 and its downstream targets (fibronectin and collagen types I and III). Figure 6B shows periodate-Schiff staining (showing glycogen-rich extracellular matrix, as well as mucosal substances such as glycoproteins, glycolipids, and mucin). [Figure 6B]Figures 6A and 6B show that compound 1 (IMR-687), in combination with angiotensin II, reduces cardiac fibrosis by blocking TGF-β1 and its downstream targets (fibronectin and collagen types I and III). Figure 6B shows periodate-Schiff staining (showing glycogen-rich extracellular matrix, as well as mucosal substances such as glycoproteins, glycolipids, and mucin). [Figure 7] Figure 7 shows that compound 1 (IMR-687), in combination with nephrectomy-aldosterone, reduces cardiac fibrosis by blocking TGF-β1 and its downstream targets (fibronectin and type I and type III collagen). [Figure 8A] Figures 8A–8C show that compound 1 (IMR-687), in combination with angiotensin II (8A) or nephrectomy-aldosterone (8B), reduces markers of myocardial inflammation. C Kelly RA et al. Circulation. 1997;95:778-781. [Figure 8B] Figures 8A–8C show that compound 1 (IMR-687), in combination with angiotensin II (8A) or nephrectomy-aldosterone (8B), reduces markers of myocardial inflammation. C Kelly RA et al. Circulation. 1997;95:778-781. [Figure 8C] Figures 8A–8C show that compound 1 (IMR-687), in combination with angiotensin II (8A) or nephrectomy-aldosterone (8B), reduces markers of myocardial inflammation. C Kelly RA et al. Circulation. 1997;95:778-781. [Figure 9] Figure 9 shows that PDE9 is overexpressed in reticulocytes and neutrophils in sickle cell disease patients, as well as in the myocardium of heart failure patients with preserved ejection fraction, suggesting that cGMP may be relatively depleted despite elevated natriuretic peptide levels in these conditions. [Figure 10]Figure 10 shows the baseline characteristics of subjects randomized to either compound 1 + HU or HU alone. Subjects had normal blood pressure, with both systolic and diastolic blood pressure within the normal range. [Figure 11] Figure 11 shows the mean NT-proBNP levels. In the compound 1+HU group, the mean baseline and 4-month follow-up NT-proBNP levels were 467 and 340 pg / ml, respectively (a mean decrease of 127 pg / ml or a 27% decrease). In the HU group, the mean baseline and 4-month follow-up NT-proBNP levels were 343 and 436 pg / ml, respectively (a mean increase of 93 pg / ml or a 27% increase). A decrease of more than 50% in NT-proBNP levels was observed at 4 months in 30% of subjects treated with compound 1+HU, but not in subjects treated with HU alone. [Figure 12] Figure 12 shows the change in NT-proBNP over 4 months as a function of baseline NT-proBNP, after randomization. In a model adjusted for the 4-month change in NT-proBNP, the main effect of compound 1+HU was significant (p=0.01), but the interaction effect of compound 1+HU with baseline NT-proBNP levels was very significant (p<0.0001). In subjects with baseline NT-proBNP levels of 400 pg / ml or higher, compound 1+HU was associated with a mean decrease of approximately 68% from baseline NT-proBNP to 4-month NT-proBNP, compared to a mean increase of 28% with HU alone. In contrast, in subjects with baseline NT-proBNP levels below 400 pg / ml, NT-proBNP levels did not change significantly with 4 months of treatment with compound 1+HU compared to HU alone. Compound 1+HU was not associated with changes in heart rate or blood pressure over 4 months compared to HU alone, suggesting that these findings were not due to hemodynamic factors. [Modes for carrying out the invention]
[0015] Detailed description of the invention Phosphodiesterases (PDEs) are a family of enzymes that degrade cyclic nucleotides, thereby regulating second messengers throughout the body at the cellular level. PDEs are attractive drug targets, as evidenced by the numerous compounds introduced into clinical trials and the market, respectively. PDEs are encoded by 21 genes functionally divided into 11 distinct families in terms of kinetic properties, substrate selectivity, expression, localization patterns, activation, and regulatory and inhibitor sensitivity. The function of PDEs is the degradation of cyclic nucleotide monophosphates, specifically cyclic adenosine monophosphate (cAMP) and / or cyclic guanosine monophosphate (cGMP), which are important intracellular mediators involved in many vital processes, including neurotransmission and the control of smooth muscle contraction and relaxation.
[0016] PDE9 is cGMP-specific (in the case of cGMP, Km cAMP is more than 1000 times), and has the lowest Km among PDEs for this nucleotide, leading to the hypothesis that it plays a crucial role in regulating cGMP levels. PDE9 is expressed at low levels throughout the brain and may potentially modulate basal cGMP.
[0017] In the periphery, PDE9 expression is highest in the prostate, intestines, kidneys, and hematopoietic cells, suggesting potential therapeutic applications in various indications beyond the central nervous system (CNS).
[0018] In this disclosure, a PDE9 inhibitor (e.g., Compound 1) is used to treat cardiac diseases including, but not limited to, heart failure, cardiac dysfunction, and cardiomyopathy.
[0019] I. Compound In the context of this disclosure, a compound is considered a PDE9 inhibitor if the amount required to reach a 50% inhibitory level for any of the three PDE9 isoforms is 10 micromoles or less, preferably less than 9 micromoles, e.g., 8 micromoles or less, e.g., 7 micromoles or less, e.g., 6 micromoles or less, e.g., 5 micromoles or less, e.g., 4 micromoles or less, e.g., 3 micromoles or less, more preferably 2 micromoles or less, e.g., 1 micromoles or less, particularly 500 nM or less. In a preferred embodiment, the IC of PDE9 50 The required amount of PDE9 inhibitor to reach the desired level is 400 nM or less, for example, 300 nM or less, 200 nM or less, 100 nM or less, or even 80 nM or less, for example, 50 nM or less, for example, 25 nM or less.
[0020] In some embodiments, the PDE9 inhibitors of this disclosure barely cross the blood-brain barrier or do not cross it at all. For example, the ratio of the brain concentration to the plasma concentration of the PDE9 inhibitors of this disclosure (brain / plasma ratio) may be less than about 0.50, less than about 0.40, less than about 0.30, less than about 0.20, less than about 0.10, less than about 0.05, less than about 0.04, less than about 0.03, less than about 0.02, or less than about 0.01. The brain / plasma ratio may be measured 30 or 120 minutes after administration of the PDE9 inhibitor.
[0021] In some embodiments, the PDE9 inhibitor may be any imidazopyrazinon PDE9 inhibitor disclosed in International Publication No. 2013 / 053690 (the entire contents of which are incorporated herein by reference).
[0022] If a compound of the present invention contains one or more chiral centers, reference to any of the compounds includes, unless otherwise specified, the compound in its pure form as an enantiomer or diastereomer, as well as mixtures of the enantiomer or diastereomer in any ratio.
[0023] In one embodiment, the PDE9 inhibitor is a compound having the structure of formula (I), or a pharmaceutically acceptable salt, solvate, or polymorph thereof: [Chemical formula] [In the formula, R 2 is cyclized with either R 1 or R 3 , and R 1 , R 2 and R 3 are as follows, R 1 when cyclized with R 2 , [Chemical formula] (In the formula, R 7 is selected from the group consisting of H, -CH3, -C2H5, and C3H7, and * indicates the cyclization point), R 1 when not cyclized, is selected from the group consisting of H and [Chemical formula] (In the formula, R 7 is selected from the group consisting of H, -CH3, -C2H5, and C3H7), R 2 is [Chemical formula] (In the formula, R 8 and R 12 are independently selected from the group consisting of H, -CH3, -C2H6, and -C3H7, and * indicates the cyclization point), and is a compound selected from the group consisting of R 3 when cyclized with R 2 , [Chemical formula] (In the formula, * indicates the cyclization point, R 9 is H, C1 - C6 alkyl, substituted C1 - C6 alkyl, branched C3 - C6 alkyl, C3 - C6 cycloalkyl, substituted C3 - C6 cycloalkyl, C6 - C10 Aryl substitution C6~C 10 Aryl, C3-C9 heteroaryl, substituted C3-C9 heteroaryl, C1-C6 alkoxy, substituted C1-C6 alkoxy, branched C3-C6 alkoxy, C3-C6 cycloalkoxy, substituted C3-C6 cycloalkoxy, C6-C 10 Aryloxy, substituted C6~C 10 (Selected from the group consisting of aryloxy, C3-C9 heteroaryloxy, and substituted C3-C9 heteroaryloxy), R 3 If not cyclized, [ka] (In the formula, R 10 It is selected from the group consisting of H, -CH3 and -C2H5, R 11 C6~C 19 Aryl substitution C6~C 10 (Selected from the group consisting of aryl, C3-C9 heteroaryl, and substituted C3-C9 heteroaryl), R 4 It is selected from the group consisting of hydrogen, -CH3, -C2H5, -C3H7, -CF3, -CN, F, and Cl. R 5 C6~C 10 Aryl substitution C6~C 10 Selected from the group consisting of aryl, C3-C9 heteroaryl, substituted C3-C9 heteroaryl, C3-C6 heterocyclyl, substituted C3-C6 heterocyclyl, C3-C6 cycloalkyl, and substituted C3-C6 cycloalkyl, R 6 It is selected from the group consisting of hydrogen, F, Cl, CN, -CH3, -C2H5, -C3H7 and -CF3, A either does not exist or is -CH2.
[0024] In some embodiments, a PDE9 inhibitor having the structure of formula (I) is selected from the group consisting of: 3-(4-fluorophenyl)-6-((3-(pyridine-4-yloxy)azetidine-1-yl)methyl)imidazo[1,5-a]pyrazine-8(7H)-one (compound P1), -6[3-(pyridine-3-yloxy)azetidine-1-ylmethyl]-3-(tetrahydropyran-4-yl)-7H-imidazo[1,5-a]pyrazine-8-one (compound P2) , 6-((3S,4S)-4-methyl-1-pyrimidine-2-ylmethyl-pyrroridine-3-yl)-3-(tetrahydropyran-4-yl)-7H-imidazo[1,5-a]pyrazine-8-one (P3, enantiomer 1, or compound 1), and 6-((3R,4R)-4-methyl-1-pyrimidine-2-ylmethyl-pyrroridine-3-yl)-3-(tetrahydropyran-4-yl)-7H-imidazo[1,5-a]pyrazine-8-one (P3, enantiomer 2).
[0025] In some embodiments, the PDE9 inhibitor is 6-((3S,4S)-4-methyl-1-pyrimidine-2-ylmethyl-pyrroridine-3-yl)-3-(tetrahydropyran-4-yl)-7H-imidazo[1,5-a]pyrazine-8-one (P3, enantiomer 1, compound 1).
[0026] In some embodiments, the PDE9 inhibitor is 6-((3R,4R)-4-methyl-1-pyrimidine-2-ylmethyl-pyrroridine-3-yl)-3-(tetrahydropyran-4-yl)-7H-imidazo[1,5-a]pyrazine-8-one (P3, enantiomer 2).
[0027] In some embodiments, the PDE9 inhibitor is in racemic form, or in an enantiomerized or pure form. [ka] Alternatively, they are selected from the group consisting of pharmaceutically acceptable salts, solvates, or polymorphs thereof.
[0028] In some embodiments, the PDE9 inhibitor is compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof. The racemic form of compound 1 (otherwise defined as compound P3) and the anhydrous form of compound 1 are described in International Publication Nos. 2013 / 053690 and 2017 / 005786. The crystalline form is described in International Publication No. 2019 / 226944. Compound 1 (IMR-687) has the following structure: [ka] 6-[(3S,4S)-4-methyl-1-(pyrimidine-2-ylmethyl)pyrrolidine-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazine-8-one (also known as compound P3, enantiomer 1, and compound P3.1); formula C 21 H 26 N6O2; Calculated molecular weight: approximately 394 g / mol
[0029] II. Pharmaceutical Compositions The disclosure further provides a method for doing so by administering a pharmaceutical composition comprising a therapeutically effective amount of any of the PDE9 inhibitors and a pharmaceutically acceptable carrier or diluent to a patient requiring treatment for heart disease. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound having the structure of formula (I), a pharmaceutically acceptable salt, solvate or polymorph thereof, and a pharmaceutically acceptable carrier, diluent or excipient. In some embodiments, the pharmaceutical composition comprises a therapeutically acceptable amount of compound 1 or a pharmaceutically acceptable salt, solvate or polymorph thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
[0030] Pharmaceutically acceptable salts This disclosure also includes salts of PDE9 inhibitors, typically pharmaceutically acceptable salts. Such salts include pharmaceutically acceptable acid addition salts. Acid addition salts include salts of inorganic acids and organic acids.
[0031] Typical examples of suitable inorganic acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, sulfuric acid, sulfamic acid, and nitric acid. Suitable organic acids include formic acid, acetic acid, trichloroacetic acid, propionic acid, benzoic acid, cinnamic acid, citric acid, fumaric acid, glycolic acid, itaconic acid, lactic acid, methanesulfonic acid, maleic acid, malic acid, malonic acid, mandelic acid, oxalic acid, picric acid, pyruvic acid, salicylic acid, succinic acid, methanesulfonic acid, ethanesulfonic acid, tartaric acid, ascorbic acid, pamoic acid, bismethylenesalicylic acid, ethanedisulfonic acid, gluconic acid, citraconic acid, aspartic acid, stearic acid, palmitic acid, EDTA, glycolic acid, p-aminobenzoic acid, glutamic acid, benzenesulfonic acid, p-toluenesulfonic acid, theophyllineacetic acid, and 8-haloteophylline, such as 8-bromoteophylline. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts are described in Berge, S M et al., J. Pharm. Sci. 1977, 66, 2 (the contents of which are incorporated herein by reference).
[0032] Furthermore, the compounds of this disclosure may exist in a non-solvated form or in a solvated form with a pharmaceutically acceptable solvent such as water or ethanol. Generally, the solvated form is considered equivalent to the non-solvated form for the purposes of this disclosure.
[0033] In some embodiments, the pharmaceutical composition contains compound 1 in a solvated form, a non-solvated form, or a crystalline / polymorphic form. In some embodiments, compound 1 exists in a non-solvated form. In some embodiments, compound 1 exists in a solvated form. In some embodiments, compound 1 exists in a crystalline form. In some embodiments, compound 1 exists in a crystalline monohydrate form.
[0034] formulation The compounds of this disclosure may be administered alone or in combination with pharmaceutically acceptable carriers, diluents, or excipients in single or multiple doses. The pharmaceutical compositions of this disclosure may be formulated with pharmaceutically acceptable carriers or diluents, as well as any other known adjuvants and excipients, in accordance with prior art, such as the techniques disclosed in Remington: The Science and Practice of Pharmacy, 22nd Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 2013.
[0035] Pharmaceutical compositions may be specifically formulated for administration via any preferred route, including oral, rectal, nasal, pulmonary, topical (including oral and sublingual), percutaneous, intracisional, intraperitoneal, vaginal, and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous, and intradermal) routes. The route will be understood to depend on the overall health and age of the person being treated, the nature of the condition being treated, and the active ingredient.
[0036] Pharmaceutical compositions for oral administration include solid dosage forms such as capsules, tablets, sugar-coated tablets, pills, lozenges, powders, and granules. If necessary, the compositions may be prepared using coatings such as enteric coatings, or formulated to provide controlled release of the active ingredient, such as sustained release or prolonged release, according to methods well known in the art. Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups, and elixirs.
[0037] Examples of pharmaceutical compositions for parenteral administration include sterile aqueous and non-aqueous injection solutions, dispersions, suspensions, or emulsions, as well as sterile powders that are reconstituted into sterile injection solutions or dispersions before use. Other preferred forms of administration include, but are not limited to, suppositories, sprays, ointments, creams, gels, inhalants, skin patches, and implants.
[0038] For parenteral routes such as intravenous, intrathecal, intramuscular, and similar administrations, the typical dose is about half the dose used for oral administration.
[0039] The disclosure also provides a process for preparing a pharmaceutical composition, comprising mixing a therapeutically effective amount of the compound of the disclosure with at least one pharmaceutically acceptable carrier or diluent.
[0040] The compounds of this disclosure are generally used as free substances or as pharmaceutically acceptable salts thereof. Such salts are prepared by conventional methods by treating a solution or suspension of the compounds of this disclosure with equimolar amounts of pharmaceutically acceptable acid. Representative examples of suitable organic and inorganic acids are listed above.
[0041] For parenteral administration, solutions of the compounds of this disclosure may be used in sterile aqueous solutions, aqueous solutions of propylene glycol, aqueous solutions of vitamin E, or in sesame oil or peanut oil. Such aqueous solutions should be buffered as needed, and the liquid diluent should first be isotonic with sufficient saline or glucose. The aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration. The compounds of this disclosure may be readily incorporated into known sterile aqueous media using standard techniques known to those skilled in the art.
[0042] Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions, and various organic solvents. Examples of solid carriers include lactose, clay, sucrose, cyclodextrin, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid, and lower alkyl ethers of cellulose. Examples of liquid carriers include, but are not limited to, syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene, and water. Similarly, carriers or diluents may contain any sustained-release material known in the art, such as glyceryl monostearate or glyceryl distearate, either alone or in combination with wax. Pharmaceutical compositions formed by combining the compounds of this disclosure with pharmaceutically acceptable carriers are then readily administered in various dosage forms suitable for the disclosed route of administration. Formulations may be conveniently provided in unit dosage forms by methods known in the pharmaceutical field.
[0043] Formulations of the present disclosure suitable for oral administration may be provided as individual units such as capsules or tablets, each containing a predetermined amount of the active ingredient and optionally a suitable excipient. Furthermore, orally usable formulations may be in the form of powders or granules, solutions or suspensions in aqueous or non-aqueous liquids, or oil-in-water or water-in-oil liquid emulsions.
[0044] When a solid carrier is used for oral administration, the preparation may be in tablet form, powder or pellet form in hard gelatin capsules, or in the form of lozenges or troches. The amount of solid carrier varies widely, but will likely be in the range of approximately 25 mg to 1 g per dose. When a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule, or sterile injectable solution such as an aqueous or non-aqueous liquid suspension or solution.
[0045] The pharmaceutical compositions of this disclosure may be prepared by conventional methods in the art. For example, tablets may be prepared by mixing the active ingredient with a conventional adjuvant and / or diluent, and then compressing the mixture in a conventional tablet press. Examples of adjuvants or diluents include corn starch, potato starch, talc, magnesium stearate, gelatin, lactose, and gum. Other adjuvants or additives commonly used for such purposes, such as colorants, flavorings, and preservatives, may be used, provided they are compatible with the active ingredient.
[0046] The pharmaceutical composition may contain at least 10% by weight, 20% by weight, 30% by weight, 40% by weight, 50% by weight, 60% by weight, 70% by weight, 80% by weight, or 90% by weight of a PDE9 inhibitor (e.g., compound 1), or a pharmaceutically acceptable salt, solvate, or polymorph thereof. In some embodiments, the pharmaceutical composition may contain at least 90% by weight, 91% by weight, 92% by weight, 93% by weight, 94% by weight, 95% by weight, 96% by weight, 97% by weight, 98% by weight, or 99% by weight of compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof.
[0047] In some embodiments, compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, is formulated as an oral administration composition. For example, it may be in the form of a solid tablet. The oral administration composition comprises at least a filler and / or processing aid. The processing aid may be a flow enhancer or a lubricant. The oral administration composition may also comprise a coating. In some embodiments, the oral administration composition comprises microcrystalline cellulose and / or pregelatinized starch as a filler. In some embodiments, the oral administration composition comprises colloidal silicon dioxide and / or magnesium stearate as a processing aid. In some embodiments, the oral administration composition comprises Opadry® II white film coating. Opadry® II is a highly productive, water-soluble, pH-independent, complete dry powder film coating system containing polymers, plasticizers, and pigments, and is capable of immediate disintegration for rapid and aggressive release. In some embodiments, the oral administration composition comprises purified water, which is removed during processing.
[0048] In some embodiments, the tablet includes a coating of about 5% to about 20% by weight (e.g., about 5%, 10%, 15%, or 20%) of the total weight of the tablet.
[0049] In one embodiment, the tablet contains pregelatinized starch in an amount of about 4% to about 6% by weight of the total weight of the tablet.
[0050] In one embodiment, the tablet contains approximately 1% to 2.5% by weight of colloidal silicon dioxide based on the total weight of the tablet.
[0051] In one embodiment, the tablet contains magnesium stearate in an amount of about 0.5% to about 1.5% by weight of the total weight of the tablet.
[0052] In some embodiments, the tablet contains pregelatinized starch, colloidal silicon dioxide, and magnesium stearate in a weight ratio of 5:2:1.
[0053] In some embodiments, the tablet includes a coating that is about 10% of the tablet's weight.
[0054] In some embodiments, compositions comprising compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, are stored at a controlled room temperature (20-25°C).
[0055] In some embodiments, a composition comprising compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, is protected from light.
[0056] In some embodiments, a composition comprising compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, is ingested with food.
[0057] dosage Typical oral dosages range from approximately 0.001 to approximately 100 mg / kg body weight per day, or any range within that range. Typical oral dosages also range from approximately 0.01 to approximately 50 mg / kg body weight per day, or any range within that range. Furthermore, typical oral dosages range from approximately 0.05 to approximately 10 mg / kg body weight per day, or any range within that range. Oral dosages are usually administered in one or more doses, typically 1 to 3 doses per day. The exact dosage will depend on the frequency and manner of administration, the sex, age, weight and overall health status of the person being treated, the nature and severity of the condition being treated, any complications being treated, and other factors apparent to those skilled in the art.
[0058] In some embodiments, a PDE9 inhibitor (e.g., compound 1), or a pharmaceutically acceptable salt, solvate, or polymorph thereof, is administered to patients in need at a dosing of less than 6.0 mg / kg or less than approximately 4.0 mg / kg. For example, compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, is administered at a dosing of approximately 0.3 to approximately 3.0 mg / kg or approximately 0.3 to approximately 1.0 mg / kg, or any range within that range. Patients may have cardiac impairment. Patients may be adults (18 years or older) or children (under 18 years).
[0059] In some embodiments, the patient is administered compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, at a dose of approximately 1 mg / kg. In some embodiments, the patient is administered compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, at a dose of approximately 3 mg / kg. In some embodiments, the patient is administered compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, at a dose of approximately 6 mg / kg. In some embodiments, the patient is administered compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, at a dose of approximately 8.0 mg / kg. In some embodiments, the patient is administered compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, at a dose of approximately 10 mg / kg. In some embodiments, the patient is administered compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, at a dose of approximately 20 mg / kg. In some embodiments, the patient is administered compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, at a dose of approximately 50 mg / kg. In some embodiments, the patient is administered compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, at a dose of approximately 60 mg / kg. In some embodiments, the patient is administered compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, at a dose of approximately 100 mg / kg. In some embodiments, the patient is administered compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, at a dose of approximately 200 mg / kg.
[0060] In some embodiments, the patient is administered at least about 1 mg / kg of compound 1 per body weight, or a pharmaceutically acceptable salt, solvate, or polymorph thereof. In some embodiments, the patient is administered at least about 2 mg / kg of compound 1 per body weight, or a pharmaceutically acceptable salt, solvate, or polymorph thereof. In some embodiments, the patient is administered at least about 3 mg / kg of compound 1 per body weight, or a pharmaceutically acceptable salt, solvate, or polymorph thereof. In some embodiments, the patient is administered at least about 4 mg / kg of compound 1 per body weight, or a pharmaceutically acceptable salt, solvate, or polymorph thereof. In some embodiments, the patient is administered at least about 5 mg / kg of compound 1 per body weight, or a pharmaceutically acceptable salt, solvate, or polymorph thereof. In some embodiments, the patient is administered at least about 6 mg / kg of compound 1 per body weight, or a pharmaceutically acceptable salt, solvate, or polymorph thereof. In some embodiments, the patient is administered at least about 7 mg / kg of compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, per the patient's body weight. In some embodiments, the patient is administered at least about 8 mg / kg of compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, per the patient's body weight. In some embodiments, the patient is administered at least about 9 mg / kg of compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, per the patient's body weight. In some embodiments, the patient is administered at least about 10 mg / kg of compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, per the patient's body weight. In some embodiments, the patient is administered at least about 20 mg / kg of compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, per the patient's body weight. In some embodiments, the patient is administered at least about 30 mg / kg of compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, per the patient's body weight. In some embodiments, the patient is administered compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, at a dose of at least about 40 mg / kg per the patient's body weight.In some embodiments, the patient is administered at least about 50 mg / kg of compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, per the patient's body weight. In some embodiments, the patient is administered at least about 60 mg / kg of compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, per the patient's body weight. In some embodiments, the patient is administered at least about 100 mg / kg of compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, per the patient's body weight.
[0061] In some embodiments, the patient is administered compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, at a dose of approximately 4.0 mg / kg per body weight. In some embodiments, the patient is administered compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, at a dose of approximately 4.5 mg / kg per body weight. In some embodiments, the patient is administered compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, at a dose of approximately 8.0 mg / kg per body weight. In some embodiments, the patient is administered compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, at a dose of approximately 8.5 mg / kg per body weight.
[0062] In some embodiments, compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, is administered to patients in need at a constant dose of approximately 100 mg to approximately 1,000 mg per day. In some embodiments, compound 1 is administered at a dose of approximately 300 to approximately 800 mg per day.
[0063] In some embodiments, compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, is administered to a patient in need at a constant dose of approximately 20 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1,000 mg, 1,100 mg, 1,200 mg, 1,300 mg, 1,400 mg, or 1,500 mg per day. In some embodiments, compound 1 is administered at approximately 400 mg per day. In some embodiments, compound 1 is administered at approximately 500 mg per day. In some embodiments, compound 1 is administered at approximately 600 mg per day. In some embodiments, compound 1 is administered at approximately 700 mg per day. In some embodiments, compound 1 is administered at approximately 800 mg per day. In some embodiments, compound 1 is administered at a dose of approximately 900 mg per day. In some embodiments, compound 1 is administered at a dose of approximately 1,000 mg per day. In some embodiments, compound 1 is administered at a dose of approximately 1,100 mg per day. In some embodiments, compound 1 is administered at a dose of approximately 1,200 mg per day. In some embodiments, compound 1 is administered at a dose of approximately 1,300 mg per day. In some embodiments, compound 1 is administered at a dose of approximately 1,400 mg per day. In some embodiments, compound 1 is administered at a dose of approximately 1,500 mg per day.
[0064] In some embodiments, compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, is administered to patients in need at doses of approximately 100 mg to approximately 1,000 mg per dose. In some embodiments, compound 1 is administered at doses of approximately 300 to approximately 800 mg per dose.
[0065] In some embodiments, compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, is administered to a patient in need at doses of approximately 20 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, or 1,000 mg. In some embodiments, compound 1 is administered at a dose of approximately 400 mg. In some embodiments, compound 1 is administered at a dose of approximately 500 mg. In some embodiments, compound 1 is administered at a dose of approximately 600 mg. In some embodiments, compound 1 is administered at a dose of approximately 700 mg. In some embodiments, compound 1 is administered at a dose of approximately 800 mg. In some embodiments, compound 1 is administered at a dose of approximately 900 mg. In some embodiments, compound 1 is administered at a dose of approximately 1,000 mg.
[0066] In some embodiments, compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, is administered to the patient, with compound 1 being administered once daily (QD).
[0067] In some embodiments, compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, is administered to the patient, with compound 1 being administered twice daily (BID). In some embodiments, compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, is administered to the patient, with compound 1 being administered three times daily (TID).
[0068] In some embodiments, compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, is administered to the patient once daily with food. Food has been shown to dramatically reduce the adverse event profile. Taking compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, with food can reduce the incidence and severity of side effects such as nausea, vomiting, and headache.
[0069] In some embodiments, compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, is administered to the patient once daily for at least 7 days, 10 days, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 1.5 years, or 2 years. In some embodiments, the patient is treated for 3 months. In some embodiments, the patient is treated for 6 months. In some embodiments, the patient is treated for 1 year. In some embodiments, the patient is treated for 1.5 years. In some embodiments, the patient is treated for 2 years, 3 years, 4 years, 5 years, 5 years or more, or for a lifetime.
[0070] The formulation may be provided in unit dosage forms by methods known to those skilled in the art. For illustrative purposes, a typical unit dosage form for oral administration may contain about 0.01 to about 1000 mg, about 0.05 to about 500 mg, or about 0.5 mg to about 200 mg.
[0071] III. Treatment method Cardiac or heart failure is a clinical syndrome characterized by a pathophysiological condition caused by abnormalities in the structure and / or function of the heart, resulting in decreased cardiac output and / or increased intracardiac pressure. The myocardium may become damaged and weakened, and the ventricles may stretch or dilate, making it difficult for the heart to efficiently pump blood to the rest of the body.
[0072] In developed countries, the incidence of heart failure is approximately 1-2% of the adult population, but rises to over 10% in those 70 years of age and older. The lifetime risk of heart failure at age 55 is 33% for men and 28% for women. Conditions that can damage or weaken the heart and lead to heart failure include, but are not limited to, coronary artery disease, hypertension, congenital heart disease, heart valve defects, abnormal heart rhythms, arrhythmias, as well as myocardial damage (cardiomyopathies) due to the toxic effects of drugs such as cocaine or certain drugs used in chemotherapy.
[0073] Heart failure can involve the left ventricle, the right ventricle, or both sides of the heart. Generally, heart failure begins on the left side, particularly the left ventricle, the heart's primary pumping chamber. There are two types of left ventricular heart failure: (1) heart failure with reduced ejection fraction (HFrEF), and (2) heart failure with preserved ejection fraction (HFpEF). Ejection fraction is an important measure of how well the heart is beating and is used to classify heart failure and guide treatment.
[0074] Natriuretic peptides (NATRIPs) are cardiac hormones released as an antagonistic mechanism against increased cardiovascular stress. The cardioprotective effects of NATRIPs occur through particulate guanylate cyclase receptors, generating the second messenger cGMP, which then acts on target organs, particularly exhibiting antiproliferative, anti-inflammatory, and anti-adhesive effects, thereby reducing the induction of cardiovascular stress. Not only are NATRIPs potent biomarkers and prognostic predictors of cardiovascular stress, but their physiological effects also counteract cardiovascular stress. The cardioprotective effects of NATRIPs are mediated through the generation of cGMP. Phosphodiesterases, particularly PDE9, break down the cGMP generated by NATRIPs.
[0075] heart failure One aspect of the present disclosure provides a method for treating a patient in need of treatment for heart failure, comprising administering to the patient a PDE9 inhibitor of formula (I), or a pharmaceutically acceptable salt, solvate, or polymorph thereof. In some embodiments, the PDE9 inhibitor of formula (I) is administered at a dose of at least 10 mg / kg per body weight. In some embodiments, the PDE9 inhibitor of formula (I) is administered at a dose of at least 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, or 10 mg / kg per body weight. In some embodiments, the PDE9 inhibitor of formula (I) is administered at a dose of 4.0 mg / kg per body weight. In some embodiments, the PDE9 inhibitor of formula (I) is administered at a dose of 4.5 mg / kg per body weight. In some embodiments, the PDE9 inhibitor of formula (I) is administered at a dose of 8.0 mg / kg per body weight. In some embodiments, the PDE9 inhibitor of formula (I) is administered at a dose of 8.5 mg / kg per body weight.
[0076] Another aspect of the present disclosure provides a method for treating a patient in need of treatment for heart failure, comprising administering to the patient a PDE9 inhibitor of formula (I), or a pharmaceutically acceptable salt, solvate, or polymorph thereof, wherein the PDE9 is administered at a dose of at least 10 mg / kg per body weight. In some embodiments, the PDE9 inhibitor is administered at a dose of at least about 15 mg / kg, at least about 20 mg / kg, at least about 25 mg / kg, at least about 30 mg / kg, at least about 35 mg / kg, at least about 40 mg / kg, at least about 45 mg / kg, or at least about 50 mg / kg per body weight.
[0077] Another aspect of the present disclosure provides a method for treating a patient in need of treatment for heart failure, comprising administering to the patient a PDE9 inhibitor of formula (I), or a pharmaceutically acceptable salt, solvate, or polymorph thereof, wherein the PDE9 inhibitor reduces atrial natriuretic peptide (ANP) and / or type B natriuretic peptide (BNP) compared to pretreatment levels.
[0078] In some embodiments, the PDE9 inhibitor of formula (I) reduces ANP in a subject. In some embodiments, the PDE9 inhibitor of formula (I) reduces ANP in a subject by at least 5%, 10%, 25%, 50%, 100%, 150%, 200%, or 250% compared to pre-treatment levels. In some embodiments, the PDE9 inhibitor of formula (I) reduces ANP in a subject by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% compared to pre-treatment levels. In some embodiments, the PDE9 inhibitor of formula (I) reduces ANP by approximately 2, 3, 4, 5, 10, 15, 20, or 25 times compared to pretreatment ANP.
[0079] In some embodiments, the PDE9 inhibitor of formula (I) reduces BNP in a subject. In some embodiments, the PDE9 inhibitor of formula (I) reduces BNP in a subject by at least 5%, 10%, 25%, 50%, 100%, 150%, 200%, or 250% compared to pre-treatment levels. In some embodiments, the PDE9 inhibitor of formula (I) reduces BNP in a subject by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% compared to pre-treatment levels. In some embodiments, the PDE9 inhibitor of formula (I) reduces BNP by approximately 2, 3, 4, 5, 10, 15, 20, or 25 times compared to pretreatment BNP.
[0080] In some embodiments, heart failure is acute heart failure, chronic heart failure, or congestive heart failure. In some embodiments, heart failure is diabetes-induced heart failure, autoimmune heart failure, or inflammatory heart failure. In some embodiments, heart failure is characterized by preserved or reduced ejection fraction.
[0081] Cardiac fibrosis Another aspect of the present disclosure provides a method for treating a patient in need of treatment for cardiac fibrosis, comprising administering to the patient a PDE9 inhibitor of formula (I), or a pharmaceutically acceptable salt, solvate, or polymorph thereof.
[0082] Cardiac fibrosis generally refers to the excessive deposition of extracellular matrix in the heart muscle. Fibrocystic cells normally secrete collagen, which provides structural support to the heart. When this process is overactivated, it leads to valve thickening and fibrosis, with white tissue accumulating primarily on the tricuspid valve, but also on the pulmonary valve. This thickening and loss of flexibility can eventually lead to valve dysfunction and right heart failure.
[0083] In some embodiments, treatment of cardiac fibrosis further includes reducing the accumulation of fibronectin and / or type I and type II collagen. In some embodiments, treatment of cardiac fibrosis further includes reducing the accumulation of fibronectin. In some embodiments, fibronectin is reduced by at least 5%, 10%, 25%, 50%, 100%, 150%, 200%, or 250%. In some embodiments, fibronectin is reduced by about 2, 3, 4, 5, 10, 15, 20, or 25 times compared to pre-treatment levels. In some embodiments, fibronectin is reduced by about 5%, 10%, 20%, 30%, 40%, or 50%, or more, compared to pre-treatment levels. In some embodiments, fibronectin is reduced by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%, or more, compared to pre-treatment levels. In some embodiments, treatment of cardiac fibrosis further includes reducing type I or type II collagen. In some embodiments, type I or type II collagen is reduced by at least 5%, 10%, 25%, 50%, 100%, 150%, 200%, or 250%. In some embodiments, type I or type II collagen is reduced by about 2, 3, 4, 5, 10, 15, 20, or 25 times compared to pre-treatment levels. In some embodiments, type I or type II collagen is reduced by about 5%, 10%, 20%, 30%, 40%, or 50%, or more, compared to pre-treatment levels. In some embodiments, type I or type II collagen is reduced by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%, or more, compared to pre-treatment levels.
[0084] inflammation Another aspect of the present disclosure provides a method for treating a patient in need of treatment for myocarditis, comprising administering to the patient a PDE9 inhibitor of formula (I), or a pharmaceutically acceptable salt, solvate, or polymorph thereof.
[0085] Cardiac inflammation, or myocarditis, is inflammation of the heart muscle (myocardium). Myocarditis affects both the heart muscle and the heart's electrical system, causing a rapid or abnormal heart rhythm (arrhythmia). Cardiac inflammation can be caused by infections, particularly from viruses or bacteria; medications; or damage to heart tissue or muscle due to autoimmune diseases, drugs, environmental factors, or other contributing factors. Most commonly, it is caused by viruses and can lead to left heart failure.
[0086] In some embodiments, inflammation is reduced by at least 5%, 10%, 25%, 50%, 100%, 150%, 200%, or 250%. In some embodiments, inflammation is reduced by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% compared to the pre-treatment level.
[0087] Biophysical effects Natriuretic peptides play a crucial role in maintaining cardiovascular homeostasis. Their properties include vasodilation, natriuresis, diuresis, and inhibition of cardiac remodeling. However, as heart failure progresses, the body becomes unable to replenish natriuretic peptides. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is used as a diagnostic agent for the diagnosis of heart disease and heart failure.
[0088] In another embodiment, a PDE9 inhibitor is used to increase or decrease biomarkers associated with heart disease, such as atrial natriuretic peptide (ANP) and type B natriuretic peptide (BNP). In another embodiment, compound 1 is used to increase or decrease biomarkers associated with heart disease, such as atrial natriuretic peptide (ANP) and type B natriuretic peptide (BNP).
[0089] Cardiac-derived atrial natriuretic peptide (ANP) hormones are released in response to atrial dilation, maintaining sodium homeostasis and inhibiting the activation of the renin-angiotensin-aldosterone system. Congestive heart failure is a clinical syndrome characterized by increased cardiac volume and pressure overload due to the inability to excrete sodium load, which is associated with increased activity of systemic neurohumoral mechanisms as well as local autocrine and paracrine mechanisms. In congestive heart failure, increased synthesis and release of this hormone result in a significant increase in circulating atrial natriuretic peptide.
[0090] Brain natriuretic peptide, or type B natriuretic peptide (BNP), is a hormone secreted by cardiomyocytes in the ventricles in response to stretching caused by increased ventricular blood volume. The physiological effects of BNP are similar to those of ANP. The net effect of these peptides is a decrease in blood pressure due to a reduction in total peripheral vascular resistance and, consequently, afterload.
[0091] In some embodiments, compound 1 is used to reduce ANP in a subject. In some embodiments, ANP may be reduced by at least 5%, 10%, 25%, 50%, 100%, 150%, 200%, or 250%. In some embodiments, compound 1 is used to reduce ANP by approximately 2, 3, 4, 5, 10, 15, 20, or 25 times compared to pre-treatment ANP. In some embodiments, ANP is reduced by approximately 5%, 10%, 20%, 30%, 40%, or 50%, or more, compared to pre-treatment levels.
[0092] In some embodiments, compound 1 is used to reduce BNP in a subject. In some embodiments, BNP may be reduced by at least 5%, 10%, 25%, 50%, 100%, 150%, 200%, or 250%. In some embodiments, compound 1 is used to reduce BNP by approximately 2, 3, 4, 5, 10, 15, 20, or 25 times compared to pre-treatment BNP. In some embodiments, BNP is reduced by approximately 5%, 10%, 20%, 30%, 40%, or 50%, or more, compared to pre-treatment levels.
[0093] In another embodiment, compound 1 is used to increase hemoglobin (Hb) levels in a subject. Hb levels may increase by at least 5%, 10%, 25%, 50%, 100%, 150%, 200%, or 250%. In some embodiments, compound 1 is used to increase Hb levels by approximately 2, 3, 4, 5, 10, 15, 20, or 25 times compared to pre-treatment Hb levels.
[0094] In some embodiments, the target hemoglobin (Hb) level increases in the range of about 0.5 to about 3.0 g / dL of total Hb. In some embodiments, the target hemoglobin (Hb) level increases by about 0.5, about 1.0, about 1.5, about 2.0, about 2.5, or about 3.0 g / dL of total Hb.
[0095] In another embodiment, compound 1 is used to increase red blood cell (RBC) levels in a subject. RBC levels may increase by at least 5%, 10%, 25%, 50%, 100%, 150%, 200%, or 250%. In some embodiments, compound 1 is used to increase RBC levels by approximately 2x, 3x, 4x, 5x, 10x, 15x, 20x, or 25x relative to baseline levels before treatment.
[0096] In yet another embodiment, compound 1 is used to increase mature RBC levels, decrease immature RBC levels, and / or increase the maturation ratio. RBC maturation is measured by calculating the ratio of immature erythrocytes (RBCs) (Ery.B: late basophilic and polychromatic) to mature RBCs (Ery.C: monochromatic and reticulocytes), i.e., Ery.B / Ery.C. Mature RBC levels may increase by at least 5%, 10%, 25%, 50%, 100%, 150%, 200%, or 250%. In some embodiments, mature RBC levels increase by approximately 2, 3, 4, 5, 10, 15, 20, or 25 times compared to the baseline level before treatment. Immature RBC levels may decrease by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, or 80%. Mature RBC levels may increase by at least 5%, 15%, 25%, 50%, 100%, 150%, 200%, or 250%. In some embodiments, the maturity ratio increases by approximately 2, 3, 4, 5, 10, 15, 20, or 25 times compared to the baseline ratio before treatment.
[0097] Combination therapy Another aspect of the present disclosure provides a method for using a PDE9 inhibitor of the present disclosure, such as Compound 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof, in combination with at least one other activator. They may be administered simultaneously or sequentially. They may exist as a mixture for simultaneous administration, or they may exist in separate containers for sequential administration.
[0098] In another embodiment of the present invention, the additional therapeutic agent is one or more of the following: angiotensin transferase inhibitors (ACEIs), β-receptor blockers, mineralocorticoid / aldosterone receptor antagonists (MRAs), diuretics, angiotensin receptor neprilysin inhibitors (ARNIs), neprilysin inhibitors (NEPIs), If channel inhibitors, angiotensin II receptor blockers (ARBs), positive inotropes, vasodilators, and hydralazine (HYD) or isosorbide dinitrate (SND).
[0099] In another embodiment of the present invention, for a second or more therapeutic agents, ACEIs include, but are not limited to, captopril, enalapril, lisinopril, and trandolapril; f3 receptor blockers include, but are not limited to, bisoprolol, carvedilol, metoprolol succinate, and nevivolol; MRAs include, but are not limited to, eplerenone and spirolactone; ARNIs include sacubitril / valsartan; NEPIs include, but are not limited to, sacubitril; If channel inhibitors include, but are not limited to, ivabradine; ARBs include, but are not limited to, candesartan and valsartan; Sex-inverting agents include, but are not limited to, digitalis cardiac glycosides such as digoxin or desranoside, F3 adrenergic receptor agonists such as dopamine, dobutamine, or dopexamine, phosphodiesterase inhibitors such as milrinone, amrinone, or enoximon, phosphocreatine or cyclohexylethylamine, and other positive inotropes; vasodilators include, but are not limited to, nitroglycerin, isosorbide dinitrate, sodium nitroprusside, and prazosin; and diuretics include, but are not limited to, furosemide, bumetanide, torasemide, bendrofluazide, hydrochlorothiazide, metrazone, indapamide, amiloride, and triamterene.
[0100] In some embodiments, additional activators include beta-blockers (carvedilol, metoprolol, bisoprolol), ACE inhibitors (enalapril (Vasotec), lisinopril (Zestril), and captopril (Capoten)), angiotensin receptor blockers (losartan), aldosterone antagonists (spironolactone (Aldactone) and eplerenone (Inspra)), digoxin (lanoxine), diuretics (furosemide (Lasix)), or ARC inhibitors (losartan (Cozaar) and valsartan (Diovan)).
[0101] In some embodiments, the additional therapeutic agent is hydroxyurea (HU).
[0102] Other activators may be different PDE9 inhibitors as disclosed herein. Other activators may be antibiotics such as penicillin, nonsteroidal anti-inflammatory drugs (NSAIDs) such as diclofenac or naproxen, opioids, or analgesics such as folic acid. In some embodiments, the other activator is folic acid.
[0103] As used herein, the term “concurrent administration” is not particularly limited and means that the PDE9 inhibitor of this disclosure and at least one other activator are administered substantially simultaneously, for example, as a mixture or in immediate order.
[0104] As used herein, the term “sequential administration” means, without particular limitation, that the PDE9 inhibitor of this disclosure and at least one other activator are administered successively or in groups, not simultaneously, with a specific time interval between administrations. The time interval may be the same or different between each administration of the PDE9 inhibitor of this disclosure and at least one other activator, and may be selected from, for example, 2 minutes to 96 hours, 1 to 7 days, or 1, 2, or 3 weeks. Generally, the time interval between administrations may be in the range of several minutes to several hours, for example, 2 minutes to 72 hours, 30 minutes to 24 hours, or 1 to 12 hours. Further examples include time intervals in the range of 24 to 96 hours, 12 to 36 hours, 8 to 24 hours, and 6 to 12 hours.
[0105] The molar ratio of the PDE9 inhibitor of this disclosure to at least one additional activator is not particularly limited. For example, when the PDE9 inhibitor of this disclosure is combined with one other additional activator in a composition, their molar ratio may be in the range of 1:500 to 500:1, or 1:100 to 100:1, or 1:50 to 50:1, or 1:20 to 20:1, or 1:5 to 5:1, or 1:1. When the PDE9 inhibitor of this disclosure is combined with two or more other activators in a composition, similar molar ratios apply. The PDE9 inhibitors of this disclosure may contain a predetermined molar weight percentage of about 1% to 10%, or about 10% to about 20%, or about 20% to about 30%, or about 30% to 40%, or 40% to 50%, or about 50% to 60%, or about 60% to 70%, or about 70% to 80%, or about 80% to 90%, or about 90% to 99% of the composition.
[0106] IV. Kits and Devices This disclosure provides various kits and devices for conveniently and / or effectively carrying out the methods of this disclosure. Typically, a kit would contain a sufficient quantity and / or number of components to enable a user to perform multiple treatments on and / or experiments on multiple subjects.
[0107] In one embodiment, the Disclosure provides a kit for treating heart disease, comprising a PDE9 inhibitor compound of the Disclosure or a combination of PDE9 inhibitor compounds of the Disclosure, optionally combined with any other active agent such as folic acid, an antibiotic preparation such as penicillin, a nonsteroidal anti-inflammatory drug (NSAIDS) such as diclofenac or naproxen, an analgesic such as opioid or folic acid.
[0108] The kit may further include packaging, instructions, and / or a delivery agent for forming the formulation composition. The delivery agent may include saline, a buffer solution, or any delivery agent disclosed herein. The amounts of each component may be modified to enable the formulation of consistent, reproducible, higher concentrations of saline or simple buffers. The components may also be modified to enhance the stability of the PDE9 inhibitor compound in the buffer solution over a period of time and / or under various conditions.
[0109] This disclosure provides devices that may incorporate the PDE9 inhibitor compounds of this disclosure. These devices include stable formulations that can be immediately delivered to targets in need, such as human patients with heart failure or cardiac fibrosis.
[0110] Non-limiting examples of devices include pumps, catheters, needles, transdermal patches, pressurized nasal delivery devices, iontophoresis devices, and multilayer microfluidic devices. The devices may be used to deliver the PDE9 inhibitor compounds of this disclosure according to a single, multiple, or divided dosing plan. The devices may also be used to deliver the PDE9 inhibitor compounds of this disclosure intradermally, subcutaneously, or intramuscularly across biological tissues. Further examples of devices suitable for the delivery of PDE9 inhibitor compounds include a medical device for intravesical drug delivery disclosed in International Publication No. 2014036555, a glass vial made of Type I glass disclosed in U.S. Patent Application Publication No. 20080108697, a drug elution device comprising a film made of a biodegradable polymer and an activator disclosed in U.S. Patent Application Publication No. 20140308336, an injection device having an injection micropump or a container containing a pharmaceutically stable preparation of an activator disclosed in U.S. Patent No. 5716988, and a reservoir, as disclosed in International Publication No. 2015023557. Examples of implantable drug delivery devices include, but are not limited to, implantable devices comprising a channel-equipped member in fluid communication with a va; a hollow fiber-based biocompatible drug delivery device having one or more layers, as disclosed in U.S. Patent Application Publication No. 20090220612; an elongated flexible device having a housing defining a reservoir containing a drug in solid or semi-solid form, as disclosed in International Publication No. 2013170069; and a bioabsorbable implantable device, as disclosed in U.S. Patent No. 7,326421. The contents of each of these are incorporated herein by reference in their entirety.
[0111] V. Definition Where used herein, the articles "a" and "an" should be understood to mean "at least one" unless explicitly stated otherwise.
[0112] As used herein, the phrase “and / or” should be understood to mean “either or both” of the elements thus combined, i.e., elements that exist in some cases associatively and in other cases separately. Unless explicitly stated otherwise, other elements other than those specifically identified by the “and / or” clause may exist, whether related to or unrelated to the specifically identified element. Thus, as a non-restrictive example, when used in combination with non-restrictive language such as “including,” a reference to “A and / or B” may, in one embodiment, refer to A excluding B (optionally including elements other than B), in another embodiment, refer to B excluding A (optionally including elements other than A), and in yet another embodiment, refer to both A and B (optionally including other elements).
[0113] Where used herein, “or” should be understood to have the same meaning as “and / or” as defined above. For example, when separating items within a list, “or” or “and / or” shall be interpreted as inclusive, that is, as including at least one (but not more than one) of several elements or their list and any additional unlisted items of their choice. Only terms that are clearly indicated as not being such, such as “one of the ~” or “exactly one of the ~” or, when used in a claim, “consisting of ~,” would refer to including several elements or exactly one element of their list.
[0114] In general, as used herein, the term “or” shall be construed only to indicate an exclusive substitution (i.e., “one or the other, but not both”) when preceded by an exclusive term such as “either,” “one of,” “only one of,” or “strictly one of.” As used in a claim, “essentially consisting of” shall have its ordinary meaning as it is used in the field of patent law.
[0115] Where used herein, the phrase “at least one” in reference to a list of one or more elements should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of every element specifically enumerated in the list of elements, nor excluding any combination of elements in the list of elements. This definition also allows for the optional presence of elements other than those specifically identified in the list of elements to which the phrase “at least one” refers, whether or not they are related to those specifically identified elements.
[0116] Therefore, in non-limiting embodiments, "at least one of A and B" (or similarly, "at least one of A or B" or similarly, "at least one of A and / or B") may, in one embodiment, refer to at least one A (and optionally, elements other than B) that optionally includes two or more A's, in which no B's exist; in another embodiment, refer to at least one B (and optionally, elements other than A) that optionally includes two or more B's, in which no A's exist; and in yet another embodiment, refer to at least one A that optionally includes two or more A's and at least one B (and optionally, elements other than A) that optionally includes two or more B's, and so on.
[0117] All transitional phrases such as "comprising," "including," "carrying," "having," "containing," "involving," and "holding" should be understood as non-restrictive, meaning they include but are not limited to.
[0118] As defined in the U.S. Patent and Trademark Office's Patent Examination Procedure Manual, only the transitional phrases "consisting of" and "essentially consisting of" are considered restrictive or semi-restrictive transitional phrases, respectively.
[0119] As used herein, “subject” or “patient” means any mammal (e.g., human) that is susceptible to a disease or disorder, such as tumorigenesis or cancer. Examples include humans, non-human primates, cattle, horses, pigs, sheep, goats, dogs, cats, or rodents such as mice, rats, hamsters, or guinea pigs. In various embodiments, a subject means one that has been or will be the subject of treatment, observation, or experimentation. For example, a subject may be one that has been diagnosed with cancer or is otherwise known to have cancer, or one that has been selected for treatment, observation, or experimentation based on known cancer in the subject.
[0120] As used herein, “treatment” or “treating” means improvement of a disease or disorder, or at least one sign or symptom thereof. “Treatment” or “treating” can also mean reducing the progression of a disease or disorder, for example, by stabilizing at least one sign or symptom, or by reducing the rate of progression, as determined by a decrease in the rate of progression of at least one sign or symptom. In another embodiment, “treatment” or “treating” means delaying the onset of a disease or disorder.
[0121] As used herein, “prevention” or “prevention” means reducing the risk of acquiring or having signs or symptoms of a given disease or disorder, i.e., preventive measures.
[0122] As used herein, the term “therapeutic dose” means the amount of a compound, material, or composition containing the compound of this teaching that is effective in producing a desired therapeutic effect. Thus, a therapeutic dose is one that treats or prevents a disease or disorder, for example, by improving at least one sign or symptom of the disorder. In various embodiments, the disease or disorder is cancer.
[0123] A dash ("-") without a space between two letters or symbols is used to indicate a substituent bond. For example, -CONH2 is bonded via a carbon atom (C). "Optional" or "optionally" means that the event or situation described thereafter may or may not occur, and that the description includes both cases in which the event or situation occurs and cases in which it does not. For example, "optionally substituted aryl" includes both "aryl" and "substituted aryl" as defined herein. With respect to any group containing one or more substituents, it will be understood by those skilled in the art that such a group is not intended to introduce any substitution or substitution pattern that is sterically impractical, synthetically unfeasible, and / or inherently unstable.
[0124] All numerical ranges in this specification include all numerical values and all numerical ranges within the ranges described. As a non-limiting example, (C1-C6) alkyls also include any one of the following: C1, C2, C3, C4, C5, C6, (C1-C2), (C1-C3), (C1-C4), (C1-C5), (C2-C3), (C2-C4), (C2-C5), (C2-C6), (C3-C4), (C3-C5), (C3-C6), (C4-C5), (C4-C6), and (C5-C6) alkyls. Furthermore, while the numerical ranges and parameters representing the broad scope of this disclosure are approximations as described above, the numerical values described in the Examples section are reported as accurately as possible. However, it should be understood that such numerical values inherently contain certain errors due to measuring instruments and / or measurement techniques.
[0125] List of Abbreviations and Terms 1 H-NMR: Proton Nuclear Magnetic Resonance Spectroscopy ADME: Absorption, Distribution, Metabolism, and Excretion AE: Adverse event AUC 0-24 Area under the concentration-time curve from 0 to 24 hours after administration BBB: Blood-brain barrier C max :Maximum plasma concentration cGMP: Cyclic guanosine monophosphate CNS: Central Nervous System CV: Coefficient of Variation CYP: Cytochrome p450 DMC: Data Monitoring Committee DMSO: Dimethyl sulfoxide DOAC: Direct-acting oral anticoagulant ECG: Electrocardiogram End of Treatment (EOT): End of Treatment FIH: First in Human FTIR: Fourier Transform Infrared Spectroscopy GC: Gas chromatography hERG: Human delayed-rectifying potassium ion channel gene HPLC: High-Performance Liquid Chromatography HU: Hydroxyurea IC: inhibitory concentration I C 50 : Semiminimum inhibitory concentration IV: Intravenous MAD: Repeated dose escalation study MTD: maximum tolerated dose NO: Nitric Oxide NOAEL: No observed adverse effect level PD: Pharmacodynamics PDE9: Phosphodiester-9 PEG: Polyethylene glycol P-gp: P-glycoprotein PIC: Capsule-encapsulated powder PK: Pharmacokinetics (study) RBC: Red blood cell RH: Relative humidity qd: Once a day QoL: Quality of Life SAD: Single dose escalation study SAE: Serious Adverse Event SD: standard deviation SEM: Standard error of the mean sGC: Soluble guanylate cyclase t 1 / 2 Half-life TK: Toxicokinetics T max: Time to reach maximum blood concentration ULN: upper limit of normality WBC: white blood cell w / w%: weight / weight percent [Examples]
[0126] It will be understood that the following examples are intended to illustrate and not limit the present disclosure. Various other examples and modifications of the foregoing description and examples will be apparent to those skilled in the art by reading the present disclosure without departing from the spirit and scope of the present disclosure, and all such examples or modifications are intended to be included within the scope of the appended claims. All publications and patents referenced herein are incorporated herein by reference in their entirety.
[0127] Example 1. Synthesis and formulation of Compound 1 Compound 1 is an enantiomer of 6-[4-methyl-1-(pyrimidine-2-ylmethyl)pyrrolidine-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazine-8-one, disclosed in International Publication No. 2013 / 053690. Compound 1 may also be prepared by chiral selective purification of 6-[4-methyl-1-(pyrimidine-2-ylmethyl)pyrrolidine-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazine-8-one prepared according to the method disclosed in International Publication No. 2013 / 053690 (the entire contents of which are incorporated herein by reference). Compound 1 may also be prepared using the method disclosed in International Publication No. 2017 / 005786 (the entire contents of which are incorporated herein by reference). Compound 1 is also known as IMR-687.
[0128] [ka]
[0129] Example 2. Effect of Compound 1 on a model of hypertension-induced heart failure with preserved election fraction (HFpEF). Systemic hypertension is the single most important comorbidity seen in HFpEF, with a reported prevalence of 60%–89% from large controlled trials, epidemiological studies, and heart failure (HF) registries. Elevated blood pressure induces changes in cardiomyocytes and fibroblasts, promoting cardiac remodeling. Furthermore, hypertension leads to vascular changes such as endothelial dysfunction, reduced coronary reserve blood flow, and decreased capillary density, all of which contribute to reduced oxygen supply. Systemic hypertension also causes arteriosclerosis, which places an unbalanced load on the heart, leading to dissociation of the ventricles and blood vessels and afterload mismatch. These changes lead to decreased systolic and diastolic function. Mice that were injected with aldosterone and had one kidney removed.
[0130] Mice that undergo unilateral nephrectomy and aldosterone infusion (with 1% NaCl intake) for 4–6 weeks develop HFpEF, accompanied by moderate hypertension, concentric left ventricular hypertrophy, pulmonary congestion, and evidence of diastolic dysfunction on echocardiography, while maintaining normal / preserved LVEF. These mice also exhibit movement disorders. At the molecular level, the left ventricular tissue of these mice shows increased natriuretic peptides, increased cardiac size and cardiac fibrosis, and increased oxidative stress.
[0131] Angiotensin II-injected mouse Administration of angiotensin II to mice for various durations (1–8 weeks) induced cardiac hypertrophy and remodeling, both in the presence and absence of hypertension, suggesting that cardiac remodeling under angiotensin II infusion is mediated by both blood pressure-dependent and blood pressure-independent factors. C57BL / 6J mice develop compensatory concentric hypertrophy and fibrosis in response to angiotensin II. Pulmonary congestion and exercise intolerance are evident and appear to be associated with angiotensin II-induced skeletal muscle abnormalities such as mitochondrial dysfunction and skeletal muscle atrophy. In summary, when the strain and dosage are optimized to reflect the human HFpEF phenotype, angiotensin II infusion appears to be a relevant HFpEF model.
[0132] Example 3. Effect of Compound 1 on an obesity and diabetes-induced heart failure with preserved election fraction (HFpEF) model. Obesity induces significant structural changes in the left ventricle, and patients with HFpEF are significantly more likely to be obese. There are multiple mechanisms by which obesity contributes to HFpEF. Increased fat accumulation promotes inflammation, insulin resistance, and dyslipidemia, impairing arteries, skeletal muscle, and bodily function, all of which are abnormalities in HFpEF patients. Diabetes is also commonly seen in HFpEF. Systemic insulin resistance and hyperglycemia induce cardiac insulin resistance, as well as imbalances in neurohormones, sympathetic nerves, and cytokines in the heart. This can trigger cardiac remodeling processes such as cardiomyocyte hypertrophy, interstitial fibrosis, and collagen modification, potentially leading to further cell damage and decreased diastolic and systolic function. db / db mouse
[0133] db / db leptin receptor-deficient mice have a point mutation in the diabetes (db) gene encoding the leptin receptor, spontaneously causing morbid obesity with severe hyperglycemia secondary to type 2 diabetes. Therefore, this model is valuable for investigating the combined contribution of obesity and type 2 diabetes to HFpEF, which is representative of this particular HFpEF phenotype. db / db mice exhibit a systemic inflammatory cytokine fingerprint, and despite the presence of both hyperinsulinemia and hyperleptinemia, the mice initially do not show cardiac hypertrophy, but eventually develop cardiac hypertrophy at old age (6 months). At the histological level, the hearts of these mice show cardiomyocyte hypertrophy, evidence of fibrosis, and capillary dilution. db / db mice appear to present with an obese / metabolic HFpEF phenotype with evidence of HF, but their LVEF is preserved.
[0134] Example 4. The role of Compound 1 in a preclinical model of HFpEF to improve cardiac function and reduce myocardial hypertrophy, fibrosis, and inflammation. Model 1: Eight-week-old C57BL / 6J male mice were intraperitoneally anesthetized with 100 mg / kg ketamine and 10 mg / kg xylazine. All mice underwent unilateral nephrectomy, followed by continuous infusion of d-aldosterone (0.30 μg / h) via an osmotic minipump. All mice were maintained on 1.0% sodium chloride drinking water. Mice were randomized to receive either vehicle or compound 1 at 60 mg / kg / day or 100 mg / kg / day for 4 or 6 weeks (36 mice, N=6 / group). Mice were housed in rooms with standard temperature and 12 / 12 hour light / dark control, and were given free access to water and standard rodent diet. Mice were euthanized 4 or 6 weeks after the start of treatment. Administration of 60 mg / kg of compound 1 in mice has been shown to be equivalent to administration of approximately 4.8 mg / kg of compound 1 in adult humans. Similarly, administration of 100 mg / kg of compound 1 to mice has been shown to be equivalent to administering approximately 8.1 mg / kg of compound 1 to human subjects.
[0135] Several biological effects were tested, including: cardiac size and cardiomyocyte hypertrophy (Figures 2A and 2B); ANP and BNP levels (right side of Figure 3A and right side of Figure 3B); PDE-9 mRNA expression levels (Figure 4B); TGF-B1 levels and downstream targets (fibronectin and type I and III collagen) (Figure 7); and myocardial inflammation biomarkers (Figure 8B). In summary, these data indicate that compound 1 (with or without nephrectomy and serial infusion of d-aldosterone) is effective in treating various forms of heart disease (e.g., myocardial inflammation, fibrosis, etc.).
[0136] Model 2: Eight-week-old C57BL / 6J male mice were anesthetized with isoflurane, and an osmotic minipump was subcutaneously implanted to continuously infuse angiotensin II in 10 mM acetate at a dose of 1.5 mg / kg per day for 4–6 weeks. The experimental animal group was randomly assigned to receive either a vehicle or compound 1 at a dose of 60 mg / kg / day or 100 mg / kg / day by forced oral administration for 4 or 6 weeks over the same period (36 mice, N=6 / group). Mice were housed in rooms with standard temperature and 12 / 12 hour light / dark control, and were given free access to water and standard rodent food. Mice were euthanized 4 or 6 weeks after angiotensin II infusion. Administration of compound 1 at 60 mg / kg in mice has been shown to be equivalent to administration of compound 1 at approximately 4.8 mg / kg in adult humans. Similarly, administration of 100 mg / kg of compound 1 to mice has been shown to be equivalent to administering approximately 8.1 mg / kg of compound 1 to human subjects.
[0137] Several biological effects were tested, including: cardiac size and cardiomyocyte hypertrophy (Figures 1A and 1B); ANP and BNP levels (Figure 3A left and Figure 3B left); PDE-9 mRNA expression levels (Figure 4A); TGF-β1 levels and downstream targets (fibronectin and type I and III collagen) (Figure 6A); and myocardial inflammation biomarkers (Figure 8A). In summary, these data indicate that compound 1 (with or without nephrectomy and serial angiotensin II infusion) is effective in treating various forms of heart disease (e.g., heart failure, cardiac fibrosis, myocardial inflammation, etc.).
[0138] Example 5. The role of Compound 1 in a preclinical model of HFpEF to improve weight loss in diabetes-related and non-diabetic-related obesity. Model 3: Obese, diabetic male db / db mice, 20 weeks old, of the BKS.Cg-Dock7m+ / +Leprdb / J strain, were randomly assigned to receive long-term treatment with either the vehicle or compound 1 at 60 mg / kg / day or 100 mg / kg / day (30 mice, n=10 / group). Treatment was administered for 8 weeks using a subcutaneous osmotic pump. Mice were housed in a room with standard temperature and 12 / 12 hour light / dark control, and were given free access to water and a standard rodent diet.
[0139] Task Outcome: We propose evaluating the following using a mouse model of HFpEF treated with compound 1 at 60 mg / kg / day or 100 mg / kg / day.
[0140] (a) Physiological measurements: Monitor heart rate (bpm) and blood pressure (mmHg) weekly using a non-invasive tail cuff blood pressure analyzer. Insulin and glucose levels at the start of treatment (day 0) and on the day of slaughter (4 or 6 weeks for models #1 and #2, and 12 weeks for model #3).
[0141] (b) Body weight (g), heart weight / body weight (mg / g), serum aldosterone level and serum angiotensin II level by ELISA.
[0142] (c) Myocardial cGMP concentration using parameter cGMP immunoassay.
[0143] (d) Left ventricular cardiomyocyte hypertrophy: mRNA expression of atrial natriuretic peptide and brain natriuretic peptide (encoded by genes Nppa and Nppb), cross-sectional area of cardiomyocytes in sections stained with hematoxylin-eosin, and diameter of cardiomyocytes in sections stained with wheat germ agglutinin.
[0144] (e) Cardiac PDE-9 expression: mRNA by real-time PCR and protein by Western blotting.
[0145] (f) Myocardial fibrosis: Fibrosis area (%) of sections stained with Masson's trichrome and PAS, mRNA expression of collagen type I and III, fibronectin and TGF-β1 by real-time PCR.
[0146] (g) Myocardial oxidative stress: Immunohistochemical analysis of sections stained with 3-nitrotyrosine antibody.
[0147] (h) Calcium-processing proteins and signaling pathways: Sarcoplasmic reticulum Ca 2+ -ATPase (SERCA2a), Ca 2+ Immunoblotting of calmodulin-dependent protein kinase II (CaMKII), protein kinase A (PKA), and phospholamban (total, phosphorus-Ser16 and phosphorus-Thr17).
[0148] (i) Myocardial inflammation: Immunohistochemical analysis of macrophage infiltration by real-time PCR, cytokine mRNA expression (IL-1b, IL-6, IL-8, IL-13, IL-17, IFN-gamma, TNF-alpha), and inflammatory markers of cardiomyocytes and plasma by proteome profiler and bioplex assay.
[0149] (j) Markers of endothelial activation: Plasma levels of soluble E-selectin (CD62E), P-cerctin (CD62P), vascular adhesion molecule 1 (VCAM-1), and intercellular adhesion molecule 1 (ICAM-1) as determined by ELISA.
[0150] (k) Pulmonary congestion: wet lung weight / dry lung weight, histological analysis of lung sections stained with hematoxylin-eosin.
[0151] (1) Renal injury and fibrosis: Histological analysis of renal sections stained with hematoxylin-eosin, and fibrosis area (%) of sections stained with Masson's trichrome and PAS; mRNA expression of type I and type III collagen, fibronectin, and TGF-beta 1 by real-time PCR. Renal function is assessed by the levels of plasma creatinine, blood urea nitrogen (BUN), urinary NGAL, and albuminuria.
[0152] (k) Model #3 (db / db): Determination of weight loss by comparing weight at the start and end of treatment; NPR-C adipose tissue mRNA expression by real-time PCR; accumulation of adipose tissue macrophages by immunohistochemistry.
[0153] Example 6. IMR-687-mediated phosphodiesterase-9 inhibition and natriuretic peptide levels in adult patients with sickle cell disease. IMR-SCD-102 is an ongoing phase 2a randomized, double-blind, placebo-controlled trial testing compound 1 (IMR-687) at 50-200 mg daily as monotherapy, or in combination with background hydroxyurea therapy (compound 1 + HU) at 50-100 mg daily. Later-stage protocol modifications enabled sample collection and characterization of NT-proBNP levels in combination cohorts (compound 1 + HU versus HU monotherapy). Plasma NT-proBNP was measured at randomization and at 4 months in 15 subjects (100% HbSS genotype). A 2:1 randomization scheme supporting combination therapy resulted in 10 subjects receiving compound 1 + HU and 5 subjects receiving HU monotherapy. Baseline, 4-month follow-up, and changes in NT-proBNP levels were quantified. Furthermore, changes in NT-proBNP levels were examined to determine if they varied with treatment and baseline NT-proBNP levels.
[0154] Baseline characteristics were similar for subjects randomized to compound 1 + HU or HU alone (Figure 10). Mean NT-proBNP levels were also analyzed (Figure 11). In the compound 1 + HU group, mean baseline and 4-month follow-up NT-proBNP levels were 467 and 340 pg / ml, respectively (mean decrease of 127 pg / ml or 27.3%). In the HU group, mean baseline and 4-month follow-up NT-proBNP levels were 343 and 436 pg / ml, respectively (mean increase of 93 pg / ml or 27.0%). A decrease of more than 50% in NT-proBNP levels was observed at 4 months in 30% of subjects treated with compound 1 + HU, but not in subjects treated with HU alone. Regarding the 4-month change in NT-proBNP, the primary effect of compound 1+HU was significant (p=0.01), but the interaction effect of compound 1+HU with baseline NT-proBNP levels was very significant (p<0.0001) (Figure 12). In subjects with baseline NT-proBNP levels of 400 pg / ml or higher, compound 1+HU was associated with a mean 67.9% decrease from baseline NT-proBNP to 4-month NT-proBNP, compared to a mean 28.0% increase with HU alone. In subjects with baseline NT-proBNP levels below 400 pg / ml, NT-proBNP levels did not change significantly with 4 months of treatment with compound 1+HU compared to HU alone. The combination of compound 1+HU was not associated with changes in heart rate or blood pressure over 4 months compared to HU alone.
[0155] The addition of compound 1 to patients receiving HU treatment appears to have a favorable cardiovascular safety profile with potential efficacy in reducing cardiovascular risk in adults with SCD, particularly those with baseline NT-proBNP levels of 400 pg / ml or higher.
[0156] Example 7. Selective PDE9 inhibition with compound 1 reduces cardiac hypertrophy and renal injury in a preclinical mouse model of cardiac failure with preserved ejection fraction. Introduction: Through the degradation of cyclic GMP, a second messenger that protects the heart and kidneys, excess PDE9 may contribute to cardiomyocyte hypertrophy, fibrosis, and renal failure, which are common features in the onset and progression of heart failure with preserved ejection fraction (HFpEF).
[0157] Selective PDE9 inhibition by compound 1 mitigates adverse cardiac and renal phenotypes in a mouse model of HFpEF.
[0158] Methods: Cardiac and renal responses to compound 1 (60 mg / kg, 100 mg / kg) compared to solvents were examined over 6–8 weeks in three adult male mouse models of HFpEF (1.5 mg / kg / day angiotensin II infusion [ang-II]; unilateral nephrectomy + 0.30 μg / h d-aldosterone infusion + 1% NaCl drinking water [neph-aldo]; and db / db [db]). Phenotypic analysis included wheat germ agglutinin staining of cardiomyocyte cross-sectional area (CSA), RT-PCR for transduction of cardiac PDE9, natriuretic peptides, inflammation and fibrosis markers; ELISA for plasma natriuretic peptides; and urinary albumin to creatinine ratio (UACR).
[0159] Results: Compound 1 reduced median cardiomyocyte size (CSA) by 54%, 58%, and 35% in the ang-II, neph-aldo, and db models compared to the vehicle (all p<0.003). Cardiac PDE9, NPPA, NPPB, COL3A1, and IL-1β expression were reduced by compound 1 in all models (Table 1). Median plasma BNP levels (pg / mL) were lower in compound 1-treated mice compared to vehicle-treated mice in all models (ang-II: 2376 vs. 5757; neph-aldo: 1216 vs. 1860; db: 830 vs. 1216) (all p<0.007), and similar results were obtained for ANP (Table 1). UACR was lower in compound 1-treated mice compared to vehicle-treated mice in all models (Table 1). There were no differences in heart rate or blood pressure between compound 1-treated mice and vehicle-treated mice. The results are shown in Table 1.
[0160] [Table 1]
[0161] The median value is displayed. P-value from Wilcoxon rank-sum test. Ang-II model (8-week-old C57BL / 6 mice were infused with 1.5 mg / h of ang-II for 6 weeks in combination with compound 1 or vehicle). Neph+d-aldo+1%NaC1 model (8-week-old C57BL / 6 mice underwent unilateral nephrectomy, followed by 6 weeks of infusion with d-aldosterone in combination with compound 1 or vehicle, and were allowed free access to 1%NaC1 drinking water). db model (20-week-old BKS.Cg-Dock7m+ / +Leprdb / J mice administered vehicle or compound 1 for 8 weeks). mRNA expression levels were normalized for GAPDH, Rpl4, and Eefle1.
[0162] Conclusion: Selective PDE9 inhibition by compound 1 was effective in preventing and treating cardiac hypertrophy and renal dysfunction in three different preclinical models of HFpEF. Compound 1 is a promising therapeutic candidate for clinical trials of human HFpEF.
[0163] While preferred embodiments of the present invention have been illustrated and described herein, it will be apparent to those skilled in the art that such embodiments are provided merely as examples. Those skilled in the art will be able to conceive of many variations, modifications, and substitutions without departing from the present invention. It should be understood that various alternatives to the embodiments of the present invention described herein may be used when carrying out the present invention. The following claims define the scope of the present invention and are intended to cover the methods and structures and their equivalents within these claims.
Claims
1. 1. A method for treating heart failure in a patient in need thereof, comprising administering to the patient 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one (Compound 1) at a dose of about 20 mg or about 50 mg.
2. The method of claim 1, wherein compound 1 is administered at a dose of about 20 mg.
3. The method of claim 1, wherein compound 1 is administered at a dose of about 50 mg.
4. The method of claim 1, wherein compound 1 is administered at a dose of 50 mg per day.
5. The method of claim 1, wherein compound 1 is administered in the form of a monohydrate.
6. The method of claim 1, wherein compound 1 is administered in the form of a monohydrate polymorph.
7. The method of claim 1, wherein compound 1 is administered twice daily.
8. 2. The method of claim 1, wherein the heart failure is acute heart failure, chronic heart failure, or congestive heart failure.
9. 2. The method of claim 1, wherein the heart failure is diabetes-induced heart failure, autoimmune heart failure, or inflammatory heart failure.
10. 2. The method of claim 1, wherein the heart failure is heart failure with preserved ejection fraction or reduced ejection fraction.
11. 10. The method of claim 1, wherein the compound 1 is administered with at least one additional therapeutic agent.
12. 12. The method of claim 11, wherein the additional therapeutic agent is selected from angiotensin transferase inhibitors (ACEI), beta-receptor blockers, mineralocorticoid / aldosterone receptor antagonists (MRAs), diuretics, angiotensin receptor neprilysin inhibitors (ARNIs), neprilysin inhibitors (NEPIs), angiotensin II receptor blockers (ARBs), vasodilators, and hydralazine (HYD) or isosorbide dinitrate (SND), or combinations thereof.
13. 12. The method of claim 11, wherein the additional therapeutic agent is selected from hydroxyurea (HU), captopril, enalapril, lisinopril, trandolapril, bisoprolol, carvedilol, metoprolol succinate, nebivolol, eplerenone, spirolactone, sacubitril, ivabradine, candesartan, valsartan, digoxin, deslanoside, dopamine, dobutamine, dopexamine, milrinone, enoximone, phosphocreatine, cyclohexylethylamine, nitroglycerin, isosorbide dinitrate, sodium nitroprusside, prazosin, ivabradine, candesartan, valsartan, furosemide, bumetanide, torasemide, bendrofluazide, hydrochlorothiazide, metolazone, indapamide, amiloride, and triamterene.
14. 12. The method of claim 11, wherein the additional therapeutic agent is angiotensin II.
